RCPT 109.24 Receptos Inc $RCPT Hit a 52 week high of 112.70

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
RCPT 109.24 Receptos Inc $RCPT Hit a 52 week high of 112.70 Currently at 109.24 -1.28 -1.16% With a day low of 108.70 and a total volume of 794,000.

RCPT Receptos Inc Recent Headline News

Receptos to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Thu Nov 06, 3:03PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Credit Suisse Healthcare Conference at The Biltmore Hotel in Phoenix, Arizona. The presentation is scheduled for Wednesday, November 12 at 8:30am. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.24 (-1.28)

Receptos posts 3Q loss
Automated Insights - Tue Nov 04, 7:19AM CST
SAN DIEGO (AP) _ Receptos Inc. (RCPT) on Tuesday reported a loss of $32.2 million in its third quarter.
RCPT: 109.24 (-1.28)

Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
RCPT: 109.24 (-1.28)

Receptos to Present at Nomura BioPharma Conference
GlobeNewswire - Mon Nov 03, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Nomura BioPharma Conference at the Mandarin Oriental Hotel in Boston. The presentation is scheduled for Thursday, November 6 at 2:15pm Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.24 (-1.28)

Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 43.37 (-0.32), WMGI: 27.95 (-0.49), CFN: 57.28 (-0.16), UTHR: 124.21 (-1.12), RCPT: 109.24 (-1.28), WMGIZ: 4.31 (-0.04)

Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
RCPT: 109.24 (-1.28)

Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 50.17 (-0.82), PTLA: 27.39 (-0.33), RCPT: 109.24 (-1.28), IG: 9.45 (-0.25)

Nasdaq stocks posting largest percentage increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
VDSI: 26.63 (+0.14), ECHO: 27.33 (-0.21), LAYN: 7.52 (+0.26), NVAX: 4.95 (-0.20), SCYX: 9.00 (+0.10), RCPT: 109.24 (-1.28), TRNX: 25.50 (-0.09), IDTI: 17.73 (-0.07), SANM: 25.60 (-0.23)

Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.39 (-0.14), KSS: 57.22 (+0.41), MU: 33.01 (-0.34), PFE: 29.92 (-0.12), HAL: 53.86 (+0.69), AMGN: 160.25 (-0.10), NQ: 7.18 (+0.20), RGC: 22.15 (-0.07), MS: 35.66 (+0.35), MSG: 75.15 (+0.27), NVAX: 4.95 (-0.20), CQB: 14.43 (+0.01), SRPT: 16.12 (-0.14), RCPT: 109.24 (-1.28), TWTR: 40.31 (-0.53), PTIE: 1.71 (-0.11)

Health Care Stocks On The Rise With Help From 3 Stocks
at The Street - Tue Oct 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
AMGN: 160.25 (-0.10), RCPT: 109.24 (-1.28), NVS: 91.76 (-0.27)

Receptos Soars After Lead Drug Racks Up Another Win
at Investor's Business Daily - Tue Oct 28, 10:46AM CDT
Receptos (RCPT) stock jumped more than 47% to a new high above 99 in morning trading on the stock market today, and the company got multiple price-target increases after its bowel-disease drug succeeded in a midstage trial. Receptos announced late...
JNJ: 108.20 (-0.81), RCPT: 109.24 (-1.28), ABBV: 61.50 (-1.21)

Stock Futures Positive, Steady; Vasco Rockets, Twitter Fades
at Investor's Business Daily - Tue Oct 28, 8:01AM CDT
Stock futures rolled up moderate gains ahead of Tuesday's open, as investors geared up for a session with many moving parts. Dow futures were steady, trading 73.1 points above fair market value. Nasdaq 100 futures were up a strong 19.4 points, and...
WHR: 175.81 (+0.97), VDSI: 26.63 (+0.14), RCPT: 109.24 (-1.28), BP: 42.06 (+0.19), TWTR: 40.31 (-0.53), AET: 82.29 (-2.41)

RECEPTOS
at Investor's Business Daily - Mon Oct 27, 5:48PM CDT
RECEPTOS (RCPT), a biotech, reported positive phase 2 trial results for its RPC1063 treatment for ulcerative colitis. Shares shot up 25.1% to 85.02.
RCPT: 109.24 (-1.28)

Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
GlobeNewswire - Mon Oct 27, 3:01PM CDT
- Study met primary efficacy and all secondary endpoints with statistical significance for patients on 1 mg dose after 8 weeks of treatment -
RCPT: 109.24 (-1.28)

Surprising Stocks That Performed Best for Billionaires in 2014
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the best for 19 billionaires who made their money investing.
BDSI: 15.50 (-0.34), ATHL: 58.34 (+0.11), VIPS: 23.34 (-0.04), ARII: 66.28 (+0.15), SBAC: 114.62 (+2.97), BIOF: 7.28 (+0.01), BKW: 32.60 (-0.72), LUV: 38.24 (+0.30), HCA: 65.75 (-3.22), LPDX: 5.23 (+0.01), DTV: 87.40 (-0.08), RCPT: 109.24 (-1.28), WMB: 55.38 (+0.67), BRK.B: 143.61 (+0.32), BRK.A: 214,970.00 (+170.00), SBGL: 7.16 (+0.24), AN: 57.59 (-0.26)

Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
GlobeNewswire - Fri Oct 03, 6:59AM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that the first patient has been treated in a Phase 2 trial of RPC4046, Receptos' development candidate for eosinophilic esophagitis (EoE). RPC4046 is a humanized monoclonal antibody directed against interleukin-13 (IL-13), a target which has been validated in other related allergic indications.
RCPT: 109.24 (-1.28)

The 5 Best Biotech Stocks in 2014...so far
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 26, 7:35AM CDT
Since the quarter is wrapping up and investors are considering their game plan heading into year-end, let's look at biotech's biggest winners for the year, why they've rallied, and whether they make sense for your portfolio . Specifically, let's...
GILD: 106.45 (-0.49), ACHN: 10.11 (-0.15), RCPT: 109.24 (-1.28), PTCT: 40.24 (-1.93), ICPT: 172.59 (-74.39), PBYI: 236.89 (-3.28)

Critical Alerts For FuelCell Energy, Receptos Inc., HD Supply Holdings Inc., Westport Innovations and Organovo Released By InvestorsObserver
PR Newswire - Thu Sep 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FCEL, RCPT, HDS, WPRT and ONVO.
WPRT: 6.06 (+0.38), FCEL: 2.11 (+0.09), ONVO: 6.97 (+0.13), HDS: 29.01 (-0.32), RCPT: 109.24 (-1.28)

Market Maker Surveillance Report. NPSP, CYTK, JDSU, INVT, MNDL, RCPT, Winning Stocks With Lowest Price Friction For Wednesday, September 10th 2014
M2 - Thu Sep 11, 4:12AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4911 companies with "abnormal" market making, 2481 companies with positive Friction Factors and 2383 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. NPS Pharmaceuticals Inc (NASDAQ:NPSP), Cytokinetics Inc (NASDAQ:CYTK), JDS UNIPHASE CORPORATION (NASDAQ:JDSU), INVESTAMERICA INC (OTC:INVT), Mandalay Digital Group Inc (OTC:MNDL), (NASDAQ:RCPT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
CYTK: 4.10 (-0.15), INVT: 1.30 (+0.02), RCPT: 109.24 (-1.28), JDSU: 13.63 (+0.21), NPSP: 27.49 (+0.15), MNDL: 3.63 (+0.30)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 332

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 541

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 225

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 130

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 242

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 135

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 222

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 134

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 228

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 176

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading

Top 5 Most Recently Viewed Articles

Bouygues Enhances Shareholder Value Through Buyback Actions

Updated Category News Views 74

Bouygues Boosts Shareholder Value with Buyback Initiatives In corporate finance, share buybacks are often adopted as a strategic way to strengthen shareholder trust and increase stock value. Recently, Bouygues SA's trading activities have shown their dedication to creating value and aligning with the interests of their shareholders. Summary of Recent Buyback Activities...

Continue Reading
Warren Buffett's Investment in Occidental Faces Major Setback

Updated Category News Views 61

Warren Buffett's Investment Challenges with Occidental Petroleum Recently, Occidental Petroleum's shares dropped by 29% since mid-April, which has a direct impact on Warren Buffett’s large investment in the company. This decline raises concerns about potential strategies for future investments. Investment Context and Current Situation Chris Bloomstran, an experienced...

Continue Reading
Datavault AI Boosts WiSA Technology for Enhanced Home Audio

Updated Category News Views 275

Enhancing Audio Experience with Datavault AI's Innovations In the ever-evolving world of audio technology, Datavault AI has made significant strides to enhance the home audio experience. Through its Acoustic Science Division's Wireless Sound Association (WiSA), the company has launched several cutting-edge solutions designed to elevate audio quality while maintaining...

Continue Reading
Turkey Central Bank's Recent Interest Rate Reduction Explained

Updated Category News Views 297

Turkey's Central Bank Interest Rate Adjustment The central bank of Turkey has recently made headlines by announcing a significant reduction in its interest rate for the second consecutive time. This move is primarily attributed to a more pronounced slowdown in inflation that has taken place recently. Rate Cut Details The Monetary Policy Committee, led by the governor, has...

Continue Reading
Embracing Inclusivity: The Proud Pair Jewelry Initiative

Updated Category News Views 350

Embracing Inclusivity: The Proud Pair Jewelry Initiative In a significant step towards inclusivity, Hong Kong Marriage Equality has joined forces with the innovative local jewellery brand Playback Concept to unveil the "Proud Pair" collection. This unique initiative reimagines traditional jewellery by incorporating essential motifs that resonate with diverse gender...

Continue Reading